Leprosy control depends exclusively on case recognition and management with multi‐drug therapy. This approach is based on recognizing and treating chronic infectious diseases with effective drug combinations limits the materialization and spread of existing drug resistant pathogens. Besides, tuberculosis educated the relapse cases that are under risk for drug resistance which can destabilize the control measures on hand. Consequently, the construction of multi‐drug therapy like approach for controlling leprosy involves systematic evaluation of treatment failures. Several studies have recognized relapses after MDT and drug‐resistant strains of Mycobacterium leprae have been identified. In this review, we describe the drugs used to treat leprosy and the need for addition of novel drugs in MDT to improve treatment of leprosy patients. © protected.